Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3950 | plasma therapy using convalescent plasma with antibody against SARS-CoV-2 Wiki | 0.71 |
drug231 | Anti-SARS-CoV-2 Human Convalescent Plasma Wiki | 0.71 |
drug1971 | Merimepodib Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D018352 | Coronavirus Infections NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to assess the safety and efficacy of merimepodib (MMPD) oral solution when administered in combination with remdesivir in adult patients with advanced COVID-19.
Description: Proportion of subjects alive at Day 28 who are not hospitalized or if hospitalized are free of respiratory failure
Measure: Number of subjects not hospitalized or, if hospitalized, free of respiratory failure Time: Day 0 to Day 28Description: Number of Adverse Events (AEs) and number & percentage of subjects experiencing AEs after administration of the first dose of study drug
Measure: Adverse Events Time: Day 0 to Day 56Description: Change in NIAID 8-point ordinal scale, where 1=Death and 8=Not hospitalized, no limitations on activities
Measure: National Institute of Allergy and Infectious Disease (NIAID) 8-Point Ordinal Scale Time: Day 0 to Day 28Description: Duration of fever
Measure: Temperature Time: Day 0 to Day 37Description: Number of deaths
Measure: Death Time: Day 0 to Day 56Description: Need and duration of mechanical ventilation
Measure: Mechanical ventilation Time: Day 0 to Day 56Description: Duration of vasopressor support
Measure: Vasopressor Support Time: Day 0 to Day 56Description: Duration of oxygen therapy via mechanical ventilation, face mask or nasal cannula
Measure: Oxygen Therapy Time: Day 0 to Day 37Description: Time to cessation of viral shedding based on absence of SARS-CoV-2 in a PCR based COVID-19 test
Measure: Cessation of Viral Shedding Time: Day 0 to Day 37Description: Change in SpO2/FiO2
Measure: Change in Oxygen Saturation/Fraction of Inspired Oxygen Time: Day 0 to Day 37Primary Objective: • To evaluate overall safety and tolerability of SIR1-365 in patients with severe COVID-19 Secondary Objectives: - To assess the clinical efficacy of SIR1-365 in patients with severe COVID-19 - To assess the effects of SIR1-365 on multiple inflammatory biomarker levels including C-reactive protein (CRP), ferritin, lymphocyte and neutrophil counts, cytokines, and chemokines - To assess the effects of SIR1-365 on biomarkers indicative of target engagement in patients with severe COVID-19 - To assess the effects of SIR1-365 on biomarkers indicative of kidney injury in patients with severe COVID-19 - To assess the effects of SIR1-365 on biomarkers indicative of cardiovascular endothelial cell damage in patients with severe COVID-19 - To characterize plasma pharmacokinetics (PK) of SIR1-365 in patients with severe COVID-19
Description: Primary Safety Endpoint
Measure: Proportion of patients with any TEAEs during the treatment period Time: Baseline to Day 14Description: Secondary Safety Endpoint
Measure: Proportion of patients with any AEs, SAEs and drug-related AEs during the study Time: Baseline to Day 14 and Day 28Description: Secondary Safety Endpoint
Measure: Proportion of patients with clinically significant abnormality in clinical laboratory tests and ECG during the study Time: Baseline to Day 14 and Day 28Description: Clinical Efficacy Endpoint
Measure: Change from Baseline to Day 7 and Day 14 in PaO2/FiO2 ratio Time: Baseline to Day 7 and Day 14Description: Clinical Efficacy Endpoint
Measure: Time to improvement of oxygenation defined as oxygen saturation (pulse oximetry) >93% and increased ≥1% from Baseline breathing only room air in the 48 hours preceding the measurement during the study Time: Baseline to Day 28Description: Clinical Efficacy Endpoint
Measure: Number of days without oxygen use during the study Time: Baseline to Day 28Description: Clinical Efficacy Endpoint
Measure: Proportion of patients with clinical improvement defined as a reduction of 2 points in the WHO ordinal scale during the study Time: Baseline to Day 28Description: Clinical Efficacy Endpoint
Measure: Number of days hospitalized during the study Time: Baseline to Day 28Description: Clinical Efficacy Endpoint
Measure: Proportion of patients free of respiratory failure during the study Time: Baseline to Day 28Description: Clinical Efficacy Endpoint
Measure: All-cause mortality rate during the study Time: Baseline to Day 28Description: Inflammatory Biomarker Measure
Measure: Change from Baseline to Day 7 and to Day 14 in plasma CRP level Time: Baseline to Day 7 and to Day 14Description: Inflammatory Biomarker Measure
Measure: Time to reach 50% reduction from Baseline in plasma CRP level during the treatment period Time: Baseline to Day 14Description: Inflammatory Biomarker Measure
Measure: Number of the patients to reach 50% reduction from Baseline in plasma CRP level during the treatment period Time: Baseline to Day 14Description: Inflammatory Biomarker Measure
Measure: Change from Baseline to Day 7 and Day 14 in serum cytokine levels Time: Baseline to Day 7 and Day 14Description: Biomarker Assessment for Target Engagement
Measure: Change from Baseline to Day 7 and Day 14 in plasma pRIP1 and pMLKL levels Time: Baseline to Day 7 and Day 14Description: Biomarker Assessment for Kidney Injury
Measure: Change from Baseline to Day 7 and Day 14 in urine NGAL and KIM-1 levels Time: Baseline to Day 7 and Day 14Description: Assessment of PK profile
Measure: Plasma drug levels Time: Baseline to Day 7 and Day 14Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports